Valproic acid is associated with cognitive decline in HIV-infected individuals: A clinical observational study

BMC Neurology

Volumn 6, Issue , 2006, Pages

  Cysique, Lucette A ^a   Maruff, Paul ^b   Brew, Bruce J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VALPROIC ACID;

ADULT; AMBULATORY CARE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; EPILEPSY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LOW DRUG DOSE; MULTIPLE REGRESSION; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OBSERVATIONAL STUDY; SENSORY NEUROPATHY; VIRUS LOAD;

COGNITION; COGNITION DISORDERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33845771742     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-6-42     Document Type: Article

References (17)

1. Cysique L, Maruff P, Brew B: Prevalence and pattern of neuropsychological impairment in HIV/AIDS-infection across pre and post- Highly Active Antiretroviral Therapy eras: a combined study of 2 cohorts. J Neurovirol 2004, 10:350-357.
2. Brew BJ: AIDS Dementia Complex. In HIV Neurology Oxford: Oxford University Press; 2001:53-90.
3. Thompson PJ, Trimble MR: Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981, 12(6):819-824.
4. Aldenkamp A. Arends J, Bootsma H, Diepman L, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, De Vocht J: Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002, 43(1):19-26.
5. Ketter TA, Post RM, Theodore WH: Positive and negative effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999, 53:S55-S67.
6. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H: Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006, 66(6):919-921.
7. Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE: Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 2003, 23(27):9162-9170.
8. Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G: Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immu Defic Syndr 2001, 28:19-27.
9. Cysique L, Maruff P, Brew B: Variable benefit in neuropsychological function in HIV infected HAART-treated patients. Neurology 2006, 66:1447-1450.
10. Heaton R, Temkin N, Dikmen S, Avitable N, Taylor M, Marcotte T, Grant I: Detecting change: A comparison of three neuropsychological methods, using normal and clinical samples. Archs Clin Neuropsychol 2001, 16(1):75-91.
11. Mollica C, Maruff P, Vance A: Development of a statistical approach to classifying treatment response in individual children with ADHD. Hum Psychopharmacol 2004, 19(7):445-456.
12. Bland J, Altman D: Calculating correlation coefficients with repeated observations: Part I - correlation within subjects. BMJ 1995, 310:446.
13. Romanelli F, Pomeroy C: Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm Des 2003, 9(18):1433-1439.
14. Hayasaka K, Takahashi I, Kobayashi Y, Iinuma K, Narisawa K, Tada K: Effects of valproate on biogenesis and function of liver mitochondria. Neurology 1986, 36(3):351-356.
15. Raskind JY, El-Chaar GM: The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000, 34(5):630-638.
16. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, et al.: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366(9485):549-555.
17. Smith SM: Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2005, 2:56.